Selinexor, pegaspargase, and dexamethasone for NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with NK/T-cell lymphoma confirmed by a tissue sample taken within the last 3 months.
- Your lymphoma is stage 1 or 2 and you have at least one tumor that can be measured.
- You have not received any prior cancer treatment (like chemotherapy, radiation, or immunotherapy).
- Your blood counts and liver and kidney function are within acceptable limits.
- You are willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a new drug called selinexor combined with lower doses of radiation therapy for patients with a rare type of lymphoma (NK/T-cell lymphoma) that starts in the nose or upper throat. The goal is to improve how well the cancer responds to treatment while reducing radiation side effects.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This study tests a new combination of three drugs (selinexor, an anti-PD-1 antibody, and a chemotherapy regimen called P-GemOx) for people with NKT-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination works better than current options.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Hear when a new NKTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.